Biotech innovators face persistent challenges in developing viral vectors that are reliable, scalable and cost-efficient. Traditional methods can limit yields, increase costs and delay progress toward the clinic.
Minaris Advanced Therapies has developed proprietary viral vector technologies that directly address these barriers, enabling therapy developers to accelerate timelines and achieve consistent quality.
SnapFast™ Plasmids
Customizable, high-performance plasmids engineered for optimal expression and yield
TESSA® AAV Production
Helper-virus-free system that increases yield up to 30 times higher compared to triple plasmid transfection across different serotypes
XOFLX™ Lentiviral Technology
Stable packaging and producer cell lines for scalable LVV production
SnapFast™ plasmids simplify design and speed development with modular, ready-to-use building blocks.
SnapFast™ plasmids, with our experts’ design experience, transform the challenging viral vector production process. SnapFast™ plasmids, featuring modular backbones and a catalog of well-characterized DNA elements, enable the quick and reliable addition of promoters, genes of interest, UTRs, and regulatory features. We design plasmids with the final application in mind, reducing design and construction cycles to build plasmids that perform effectively from discovery through GMP manufacturing.
Minaris technologies are built to move programs forward. SnapFast™ accelerates plasmid design. TESSA® raises AAV yields, quality and reduces costs. XOFLX™ ensures scalable and consistent lentiviral supply. Together, these platforms give biotech innovators a reliable path from discovery to global commercialization.
Minaris integrates these technologies with robust testing services, providing a complete solution that reduces risk and accelerates timelines. With more than 1,700 developed assays and 25+ commercial lot release programs supported, our track record instills confidence in developers at every stage of development.
intro-section does not exist
Minaris Advanced Therapies is dedicated to helping innovators in cell and gene therapy succeed. Whether you are in early-stage development or preparing for commercial launch, our end-to-end expertise, global reach and commitment to quality make us the ideal partner for cell and gene therapy manufacturing and GMP biosafety and analytical testing of all biologics.
